Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated daily nebulized RPL554 in allergic asthma
NL-OMON35912Phase 2Active, not recruiting
- Sponsor
- Verona Pharma
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ensifentrine in asthma and allergic asthma (2 arms), sponsored by Verona Pharma. Primary endpoint: FEV1 over 6 hours on days 1, 3, and 6. Started May 2011; status: active, not recruiting.
02
Drugs
ensifentrine
03
Conditions
asthmaallergic asthma
Beyond the preview
Go deeper on NL-OMON35912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35912.